Etanercept — CPB 0315 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0315 covering etanercept (Enbrel) billing, effective January 5, 2026. Prescriber specialty requirements, biomarker testing documentation, and step therapy criteria all changed — here's what your billing team needs to do now.

Aetna's etanercept coverage policy under CPB 0315 now spells out exactly which specialist must prescribe the drug for each indication, and it tightens the biomarker and step-therapy ladder your team must document before submitting a claim. The primary billing code is HCPCS J1438 (injection, etanercept, 25 mg), and supporting lab codes — including CPT 86200 (anti-CCP antibody), 86430/86431 (rheumatoid factor), 86140/86141 (C-reactive protein), and 85651/85652 (ESR) — now carry direct weight in medical necessity determinations. If your documentation doesn't match what Aetna now requires, expect a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Etanercept (Enbrel) — CPB 0315
Policy Code	CPB 0315
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Rheumatology, Dermatology, Oncology, Hematology
Key Action	Audit your etanercept prior authorization packets for prescriber specialty, biomarker results, and step-therapy documentation before submitting any new or renewal PA after January 5, 2026

---

Aetna Etanercept Coverage Criteria and Medical Necessity Requirements 2026

The real issue with CPB 0315 is the prescriber specialty gate. Aetna now requires that etanercept be prescribed by — or in documented consultation with — a specific specialist depending on the indication. This is a harder requirement than it looks, and it will generate denials if your practice doesn't flag it upfront.

Here's how the prescriber mapping breaks down:

If a primary care physician or hospitalist is managing etanercept without documented specialist consultation, the prior authorization will fail. Full stop.

Rheumatoid Arthritis — The Criteria Are Layered

For RA — which is the most common etanercept indication in most practices — the coverage policy splits into two tracks.

Track 1 (Expedited): The member received a biologic or targeted synthetic DMARD (like Rinvoq or Xeljanz) for moderately to severely active RA within the past 120 days. If that's documented, Aetna will consider etanercept medically necessary without the full step-therapy workup.

Track 2 (Full Step Therapy): The member has not had a recent biologic. Here, you must document both a biomarker result and step-therapy failure.

For biomarkers, the policy presents two parallel alternatives. The member must meet one of the following:

#	Covered Indication Copy
1	Tested for RF (CPT 86430 or 86431) or anti-CCP (CPT 86200) with a positive result on either, or
2	Tested for all three panels: RF, anti-CCP, and CRP (CPT 86140 or 86141) or ESR (CPT 85651 or 85652)

These are two separate qualifying paths — not a primary test and a fallback. Your prior auth packets must include the actual lab documentation, not a clinical notation that labs were checked.

Step Therapy for RA — It's More Complex Than a Single MTX Failure

Aetna's step therapy for RA runs through methotrexate (MTX) first, then branches based on tolerance and response. There are three sub-tracks:

#	Covered Indication Copy
1	MTX trial completed (3 months, max titrated dose of at least 15 mg/week), with inadequate response: Member must also show failure of at least one combination csDMARD trial (hydroxychloroquine and/or sulfasalazine), or document an intolerable adverse event or contraindication to those agents, or have moderate to high disease activity.
2	MTX trial not completed due to intolerance: Member must show either a combination csDMARD failure, a leflunomide failure, an adverse event to leflunomide/hydroxychloroquine/sulfasalazine, contraindications to all three, or moderate to high disease activity.
3	MTX contraindicated or causes intolerable adverse event: Similar requirements apply for alternative csDMARD trials before etanercept is approved.

The 120-day lookback window on prior biologics is the one shortcut through all of this. If your RA patient has been on any biologic or targeted synthetic recently, document that clearly and skip the step-therapy ladder.

Prescriber Specialty Requirement Affects Your Workflow More Than You Think

If you're a multi-specialty group or a PCP managing a complex patient, flag this now. The Aetna etanercept coverage policy is not flexible here. "In consultation with" can work — but that consultation must be documented in the chart. A verbal hand-off won't satisfy a prior auth reviewer.

---

Aetna Etanercept Exclusions and Non-Covered Indications

The policy summary provided doesn't enumerate a standalone list of excluded indications beyond those not listed under the covered categories. However, the biomarker and step-therapy requirements function as practical exclusions.

If a patient's indication isn't on the covered list — or if the prescribing specialty doesn't match — Aetna will not approve etanercept. Any claim submitted without prior authorization and matching documentation will result in a claim denial. Reimbursement recovery on those is extremely difficult.

One area to watch: ICI-related toxicity and ICI-related inflammatory arthritis are covered, but only with the right prescriber. Dermatologists can cover ICI-related toxicity but not ICI-related inflammatory arthritis. Rheumatologists can cover ICI-related inflammatory arthritis but not ICI-related toxicity. Get the ordering specialty wrong, and you'll lose the claim.

If your practice sees oncology patients on checkpoint inhibitors who develop inflammatory complications, coordinate with your compliance officer before January 5, 2026. The prescriber routing for these two indications is easy to confuse.

---

Coverage Indications at a Glance

---

Aetna Etanercept Billing Guidelines and Action Items 2026

These are the specific steps your billing team and prior authorization staff need to take before submitting claims under the updated CPB 0315 Aetna policy.

Copy Action Items

If your practice has a high volume of etanercept patients across multiple indications, talk to your compliance officer before the effective date. The layered specialty-plus-indication matrix is where most practices will slip.

---

CPT, HCPCS, and ICD-10 Codes for Etanercept Under CPB 0315

Primary Billing Code — Covered When Selection Criteria Are Met

Code	Type	Description Copy
J1438	HCPCS	Injection, etanercept, 25 mg

Supporting Lab and Diagnostic Codes

These codes document medical necessity criteria. Aetna requires evidence of biomarker testing. Include results from these codes in your PA packet.

Arthrocentesis Codes (Procedure Support)

Chest Radiology Codes (TB/Baseline Screening)

Chemotherapy Administration Codes

The full CPB 0315 policy includes 50 chemotherapy administration codes (CPT 96401–96450). The source policy data groups these codes under the CD11c expression and DNA methylation biomarker context. These codes are listed in full in the Aetna policy document. Review the complete policy for the applicable clinical grouping before billing these codes against J1438 authorizations.

Ancillary HCPCS Codes

The following HCPCS codes appear in the CPB 0315 policy under a grouping that references sulfasalazine, leflunomide, clindamycin, metronidazole, and rifampicin. Review the full policy document for the specific clinical context before billing these codes.

Code	Type	Description Copy
J0120	HCPCS	Injection, tetracycline, up to 250 mg
J0390	HCPCS	Injection, chloroquine hydrochloride, up to 250 mg
J0702	HCPCS	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg

ICD-10-CM Codes

The CPB 0315 source data includes 60 ICD-10-CM codes, but the full code table was not available in the provided policy excerpt. Review the complete Aetna CPB 0315 policy document for the full ICD-10-CM list, and confirm code-to-indication alignment in your PA submission.

---